Fact based stock research
Jointown Pharmaceutical (SHSE:600998)

Jointown Pharmaceutical stock research in summary

Jointown Pharmaceutical shares are less expensive than other comparable stocks. They are safely financed, are good value and show above average growth. We recommend evaluating whether the future of the company Jointown Pharmaceutical is really as difficult as the low price of the stock suggests. If you believe that the future of the company is market-typical or even better, then this could be an argument for a share purchase.

Latest Obermatt Ranks


Value Rank	75
Growth Rank	60
Safety Rank	100
Combined Rank	100

Country	China
Industry	Health Care Distributors
Index	SSE Composite
Size class	XX-Large

July 12, 2019. Stock data may be delayed. Login to get the most recent research.

Add to Watchlist

Similar Stocks

Google: Jointown Pharmaceutical

News	Videos
Wikipedia about Jointown Pharmaceutical	Management
Employee Satisfaction	Customer Satisfaction

Research History: Jointown Pharmaceutical

RESEARCH HISTORY	2016	2017	2018	2019
VALUE
VALUE	52	52	74	75
GROWTH
GROWTH	80	93	46	60
SAFETY
SAFETY	58	58	62	100
COMBINED
COMBINED	80	80	69	100

Last update of Combined Rank: 12-Jul-2019. Financial reporting date used for calculating ranks: 31-Mar-2019. Stock research history is based on the Obermatt Method. The higher the rank, the better Jointown Pharmaceutical is in the corresponding investment strategy.

Value Metrics in Detail

VALUE METRICS	2016	2017	2018	2019
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)	87	87	86	85
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)	35	35	54	70
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)	64	60	68	74
DIVIDEND YIELD
DIVIDEND YIELD	1	1	42	32
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE	52	52	74	75

Last update of Value Rank: 12-Jul-2019. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Jointown Pharmaceutical; except for dividend yield where the rank is higher, the higher the yield.

Growth Metrics in Detail

GROWTH METRICS	2016	2017	2018	2019
REVENUE GROWTH
REVENUE GROWTH	89	93	42	72
PROFIT GROWTH
PROFIT GROWTH	63	63	80	58
STOCK RETURNS
STOCK RETURNS	51	60	26	30
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH	80	93	46	60

Last update of Growth Rank: 31-Mar-2019. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Jointown Pharmaceutical.

Safety Metrics in Detail

SAFETY METRICS	2016	2017	2018	2019
LEVERAGE
LEVERAGE	43	30	38	42
REFINANCING
REFINANCING	95	87	96	96
LIQUIDITY
LIQUIDITY	28	13	38	75
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY	58	58	62	100

Last update of Safety Rank: 5-Jul-2019. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Jointown Pharmaceutical and the more cash is available to service its debt.

Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Jointown Pharmaceutical from July 12, 2019.

We invest in our stock tips ourselves and openly publish the returns of our portfolio. That's how much we believe in our stock research. Subscribe to the top 10 stocks for 100 markets conveniently by e-mail.